TIBH

• Immunology
• Genetic diseases
• Oncology

TIBH is the only national healthcare integrator that aims to develop alternatives to conventional bioproduction by using microbial cell factories and developing adapted bioprocesses:

• • Omics analysis (Transcriptomics, Genomics, Metabolomics, Fluxomics)
  • Protein design and engineering (Strain characterisation)
  • Synthetic biology (DNA assembly, Strain engineering, Phenotypic screening)
  • Bioprocess development (Optimisation of culture media, Production of target molecules and recombinant proteins by fermentation, Development of production methods in bioreactors, Monitoring of physiological state by flow cytometry)
  • Scale-up & DSP

• Orbitrap Exploris 120 high resolution mass spectrometer
• Multicultivator MC1000 – OD – Mix (PSI, Photo Systems Instruments)
• Automated chromatographic screening/purification system
• 50L single-use bioreactor for GMP-like production

Toulouse Biotechnology Institute

TIBH (Toulouse Industrial Biotechnology for Health) was accredited as an industrial integrator for production in the healthcare sector in 2020. The integrator’s accreditation was renewed in 2022 as part of the ANR’s ‘Biotherapy-Bioproduction Integrators’ call for projects. This funding is part of the National Strategy for Accelerating Biotherapies and Bioproduction of Innovative Therapies of the France 2030 programme. TIBH brings together CRITT Bio-Industries, TBI and TWB.

Objective :  

TIBH’s objective is to support the development of new ways of producing biomedicines based on industrial biotechnologies, while meeting France 2030’s ambition of creating the medical devices of tomorrow. To achieve this, it provides the skills and biological tools required for the production of proteins, therapeutic antibodies and nucleic acids to developers of projects to develop technologies for the production of innovative therapies, offering a continuum that bridges and connects translational academic research with industrial-scale production.

Missions :

• Developing effective, economical solutions tailored to the needs of industry
• Offering alternatives to conventional bioproduction thanks to microbial cell factories
• Determination, acceleration and innovation in the development of bioprocesses and innovative therapies.

• ISO9001

• Academic
• PHAEOmAbs: The aim of this project is to develop innovative approaches for increasing the production yield of monoclonal antibodies in the microalga Phaeodactylum tricornutum.
  • The project brings together four partners: the University of Rouen Normandie (project leader), TIBH, IFREMER and CEA Cadarache.
  • This project is part of the ANR Grand Défi Biomedicaments – Nouveaux systèmes d’expression call for projects.

Industrial

• Magi@Line: The project involves the development of an online control tool for real-time monitoring of bioprocesses such as the production of therapeutic antibodies. It is being developed in collaboration with the start-up MagIA Diagnostics.
  • This project is part of the BPI Grand Défi Biomédicament call for projects – Improving yields and controlling production costs.